Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 11, 2016
Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance Aug 8, 2016
Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study Aug 3, 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations Jul 20, 2016
Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer Jun 23, 2016
Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel Jun 15, 2016
Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform May 31, 2016
Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel May 25, 2016
Cellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference May 24, 2016
